Mission BioCapital launches Platinum Program to empower biotech startups with funding and lab access across global cities in United States Canada Europe and Japan

Venture capital firm Mission BioCapital is opening applications for its 2026 Platinum Program, a global initiative designed to support early-stage life sciences startups with funding, infrastructure, and expert guidance.

Alongside the announcement, the firm also revealed its 2025 cohort, which received a combined $4 million in backing and extensive development support.

The Platinum Program continues to position Mission BioCapital as a key player in nurturing breakthrough biotechnology ventures by connecting them with a wide network of industry leaders and resources.

Backed by Major Industry Players

The initiative is supported by a strong group of sponsors, including AbbVie, Ono Venture Investment, Toronto Innovation Acceleration Partners, Connecticut Innovations, Alloy Therapeutics, HitGen, CCRM, Goodwin, Norton Rose Fulbright, and van den Boom & Associates.

These partnerships allow the program to offer startups a combination of financial backing, legal and advisory services, and cutting-edge research tools—creating a comprehensive launchpad for emerging biotech companies.

What Selected Startups Will Receive

Up to eight winners of the 2026 Platinum Program will benefit from a highly structured support package designed to accelerate growth and reduce early-stage risk.

Each selected startup will gain:

• Access to a dedicated lab bench within one of 31 incubators across 22 global cities, spanning the U.S., Canada, Europe, and Japan
• Pre-seed funding of up to $500,000, contributed by Mission BioCapital and its partners
• Drug discovery services from Alloy Therapeutics and HitGen to help identify and refine lead candidates
• Consulting and advisory services from the CCRM network
• Legal, intellectual property, and financial support from firms like Goodwin and Norton Rose Fulbright
• Scientific and business mentorship from experienced leaders across the MBC ecosystem

This integrated approach aims to give startups both the capital and the technical foundation needed to move from concept to early development.

Application Timeline and Process

Applications for the 2026 program open on April 1 and will close on May 15, 2026.

Interested startups can apply online through Mission BioCapital’s official website, with only non-confidential information required during submission.

Suggested Readings (News continues below)

Scrum Ventures launches global startup program expansion unlocking innovation opportunities and business partnerships in Hokkaido Japan

Businessman Gavin Shaw shocks police with chilling prison question after fatal stabbing of estranged wife Michele Kennedy in Warrington Cheshire

Bruno Tonioli urges BBC bosses to reject male host plan and preserve female-led Strictly Come Dancing tradition in United Kingdom

Italian football faces shocking collapse as Gennaro Gattuso departure and federation resignations deepen crisis in Italy

Winners will be announced in the summer of 2026, with selected teams gaining immediate access to the program’s full suite of resources.

Spotlight on the 2025 Platinum Program Winners

Alongside the new announcement, Mission BioCapital also highlighted nine companies selected for its 2025 Platinum Program, supported in partnership with Eli Lilly and Company, Ono Venture Investment, Alloy Therapeutics, HitGen, Goodwin, and van den Boom & Associates.

The selected startups are tackling a wide range of critical medical challenges:

• Beech Biotech (Copenhagen) is developing monoclonal antibodies designed to treat pregnancy complications without crossing the placenta
• Enodia Therapeutics (Paris) focuses on selective small molecules targeting Sec61 for cancer and immune-related diseases
• Fletcher Biosciences (Cambridge, MA) is advancing precision immunotherapies for safer, more targeted treatment
• Laurel Biotherapeutics (Cambridge, MA) is working on therapies addressing cardiovascular, inflammatory, and metabolic disorders
• Overture Therapeutics (Cambridge, MA) is developing antibody-based treatments aimed at obesity and metabolic disease
• ResNovas Therapeutics (San Francisco) is targeting previously “undruggable” proteins in oncology
• Seen Therapeutics (San Francisco) uses computational proteomics to design cancer-targeting therapies
• Skape Bio (Copenhagen) is creating miniprotein therapies for complex drug targets
• State 4 Therapeutics (New Haven, CT) is developing oral therapies to improve weight loss and metabolic health

Impact and Consequences

The Platinum Program reflects a growing trend in biotech: combining venture capital with hands-on scientific infrastructure and cross-industry collaboration.

By offering lab space, funding, and technical expertise under one umbrella, Mission BioCapital reduces the typical barriers that slow down early-stage biotech innovation.

For startups, this can mean faster development timelines, reduced financial risk, and improved chances of reaching clinical milestones.

For the broader life sciences ecosystem, it encourages more innovation in critical areas such as oncology, metabolic disease, and immune disorders.

The program also strengthens global collaboration by attracting startups from multiple regions, helping to diversify research and development pipelines.

What’s Next?

With applications opening in April 2026, Mission BioCapital is expected to attract a wide pool of early-stage biotech innovators from around the world.

The firm will evaluate candidates based on scientific promise, innovation potential, and scalability.

Following selection, the chosen startups will enter MBC’s incubator network and begin working closely with mentors, researchers, and partner organizations to advance their technologies.

Looking ahead, the success of the 2026 cohort could further establish Mission BioCapital as a leading force in early-stage biotech investment and development.

Summary

Mission BioCapital is expanding its global biotech support program with a new 2026 Platinum Program, offering funding, lab space, and expert mentorship to early-stage startups.

Backed by major industry partners, the initiative builds on the success of its 2025 cohort, which received $4 million in funding and broad support across multiple therapeutic areas.

Bulleted Takeaways

• Mission BioCapital has opened applications for its 2026 Platinum Program
• The program is backed by major industry partners including AbbVie, Alloy Therapeutics, and HitGen
• Up to eight startups will receive funding, lab access, and mentorship support
• Each selected company can receive up to $500,000 in pre-seed capital
• Applications run from April 1 to May 15, 2026
• Nine startups were selected for the 2025 cohort, receiving $4 million in total funding
• The program supports innovations in oncology, metabolic disease, immunotherapy, and more
• Mission BioCapital continues to expand its global biotech incubator network across 22 cities